ArticleScientific reports2025
Ursolic and oleanolic acids suppress MNNG induced malignant transformation of human gastric mucosal epithelium by regulating the PI3 K/AKT pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elucidating the dual regulation of apoptosis and migration by Ajugasterone C in AGS cells via the PI3K/AKT pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Berberine hydrochloride (Ber) is the primary active compound in the traditional Chinese medicine 'Huanglian'. Ursolic acid (UA) and oleanolic acid (OA) are the main triterpenoids extracted from 'Tengligen'. Notably, both Ber and UA/OA exhibit antitumour activity. This study aimed to investigate the role of Ber and UA/OA in N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced malignant transformation of the human gastric mucosal epithelium and explore the underlying mechanism. Using network pharmacology and molecular docking, we analysed the molecular mechanisms of Ber and UA/OA in treating precancerous lesions of gastric cancer (PLGC). Our results revealed that Ber and UA/OA regulate the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway. To simulate PLGC, we established malignant cells (MCs) as an in vitro cellular model using MNNG. Our results showed that Ber and UA/OA significantly inhibited the epithelial-mesenchymal transition in MCs. Notably, UA/OA more effectively inhibited MC-colony formation and cell invasion and induced MC apoptosis than Ber. Mechanistically, UA/OA significantly suppressed the PI3K/AKT/nuclear factor-kappa B (NF-κB) p65/NACHT, LRR, and pyrin domain-containing protein 3 (NLRP3) pathway. However, the PI3K/AKT agonist 740YP reversed these effects and attenuated UA/OA-induced apoptosis. In conclusion, UA/OA significantly inhibited cell-clone formation and invasion, induced apoptosis, and inhibited the malignant transformation of MCs by regulating the PI3K/AKT/NF-κB p65/NLRP3 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.